2016_Head & Neck COURSE BOOK

Treatment-Related Select AEs

Nivolumab (n = 236)

Investigator’s Choice (n = 111)

Any grade n (%)

Grade 3–4 n (%)

Any grade n (%)

Grade 3–4 n (%)

Event

Skin

37 (15.7) 18 (7.6) 16 (6.8)

0

14 (12.6)

2 (1.8)

Endocrine

1 (0.4)

1 (0.9)

0

Gastrointestinal

0

16 (14.4)

2 (1.8) 1 (0.9)

Hepatic

5 (2.1) 5 (2.1) 3 (1.3)

2 (0.8) 2 (0.8)

4 (3.6) 1 (0.9) 2 (1.8)

Pulmonary

0

Hypersensitivity/Infusion reaction

0

1 (0.9)

Renal

1 (0.4)

0

2 (1.8)

1 (0.9)

Select AEs: AEs with potential immunologic etiology that requires monitoring/intervention